Sugi Predict

Sugi Predict / Compounds / SCHEMBL334306

SCHEMBL334306

SCHEMBL334306

Nc1cccc2nccn12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK8 P49336 2/20 0.53
▸ ROCK1 Q13464 2/20 0.53
▸ DYRK1A Q13627 2/20 0.53
▸ CHEK1 O14757 1/20 0.53
▸ MAP4K4 O95819 1/20 0.53
▸ CSF1R P07333 1/20 0.53
▸ PRKACA P17612 1/20 0.53
▸ KDR P35968 1/20 0.53
▸ MAP2K1 Q02750 1/20 0.53
▸ ACVR1 Q04771 1/20 0.53
▸ MAP4K2 Q12851 1/20 0.53
▸ AURKB Q96GD4 1/20 0.53
▸ DYRK1B Q9Y463 1/20 0.53
▸ FLT1 P17948 1/20 0.47
▸ CDK9 P50750 1/20 0.47
▸ LIMK1 P53667 1/20 0.47
▸ CLK4 Q9HAZ1 1/20 0.47
▸ ADORA3 P0DMS8 1/20 0.42
▸ DRD1 P21728 7/20 0.35
▸ CDK4 P11802 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL9692647 0.98 CDK8 (0.52) CDK8ROCK1DYRK1ACHEK1MAP4K4
Hydrochloric Acid SCHEMBL5442637 0.98 CDK8 (0.52) CDK8ROCK1DYRK1ACHEK1MAP4K4
SCHEMBL5487220 0.78 ADORA3 (0.42) CDK8ROCK1DYRK1ACHEK1MAP4K4
SCHEMBL260187 0.74 CDK8 (0.53) CDK8ROCK1DYRK1ACHEK1MAP4K4
SCHEMBL22836801 0.74 CDK8 (0.53) CDK8ROCK1DYRK1ACHEK1MAP4K4
SCHEMBL18324191 0.74 CDK8 (0.53) CDK8ROCK1DYRK1ACHEK1MAP4K4
SCHEMBL7896883 0.74 CDK8 (0.58) CDK8ROCK1DYRK1ACHEK1MAP4K4
SCHEMBL21352246 0.74 CDK8 (0.53) CDK8ROCK1DYRK1ACHEK1MAP4K4
SCHEMBL4770221 0.74 CDK8 (0.53) CDK8ROCK1DYRK1ACHEK1MAP4K4
SCHEMBL260258 0.74 CDK8 (0.56) CDK8ROCK1DYRK1ACHEK1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0930062-A1 Compositions containing imidazo-pyridine derivatives for dying keratinous fibres and process L'OREAL (FR) 1999-07-21 — — EP claimed
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 — — US disclosed
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND SHOUYAO HOLDINGS BEIJING CO LTD (CN) 2025-07-10 — — US disclosed
CN-119528824-A 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2025-02-28 — — CN disclosed
EP-4501912-A1 NOVEL HETEROCYCLIC COMPOUND Shouyao Holdings (Beijing) Co., Ltd. (CN) 2025-02-05 — — EP disclosed
CN-113166078-B 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2024-11-19 — — CN disclosed
CN-118475560-A Novel heterocyclic compound 首药控股(北京)股份有限公司 2024-08-09 — — CN disclosed
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. 2024-05-30 — — US disclosed
WO-2024073073-A2 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-04-04 — — WO disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 — — US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 — — EP disclosed
EP-1820504-A1 IMINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2007-08-22 — — EP disclosed
US-20070135452-A1 Nitrogen-containing fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-14 — — US disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 — — US disclosed
US-5980585-A NONTOXIC; HAIR DYE L'OREAL (FR) 1999-11-09 — — US disclosed
EP-0930062-A1 Compositions containing imidazo-pyridine derivatives for dying keratinous fibres and process L'OREAL (FR) 1999-07-21 — — EP disclosed
US-3936435-A Cationic heterocyclic-azo-heterocyclic compounds from 5-aminoimidazo-(1,2-A)pyridines EASTMAN KODAK COMPANY (US) 1976-02-03 — — US disclosed
US-3936435-A Cationic heterocyclic-azo-heterocyclic compounds from 5-aminoimidazo-(1,2-A)pyridines EASTMAN KODAK COMPANY (US) 1976-02-03 — — US disclosed
US-3928309-A Cationic dyes from 5-aminoimidazo-(1,2-A)-pyridines CIBA-GEIGY CORPORATION, A CORP. OF NEW YORK 1975-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135452-A1 Nitrogen-containing fused heterocyclic compounds NPY4R, NR4A3, NR3C2 CDK8 2372/4885ROCK1 2444/4885DYRK1A 1668/4885
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND MAPT, MNAT1, MAT2A CDK8 1389/4885ROCK1 4323/4885DYRK1A 4231/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 CDK8 1245/4885ROCK1 1295/4885DYRK1A 860/4885
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF LRRK2, MAP3K20, MAP3K5 CDK8 462/4885ROCK1 317/4885DYRK1A 309/4885
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 CDK8 2410/4885ROCK1 4271/4885DYRK1A 1478/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A CDK8 339/4885ROCK1 2870/4885DYRK1A 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.